Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Current Attitude - another episode

Our 10Q only has to include our share of PDS revenue/exp on one line of our financial statement:  'Equity Earnings in Affiliate".  Thus, we can only report our share of what PDS booked.  So if PDS did not book Feburary's announced licenses in February then it is impossible for us to book our share of them. 

This all then leads to the next question (that I postulated yesterday):  What is PDS's revenue recognition policy?  It seems it may vary from ours in that licenses announced in February would likely have been booked if PDS followed PTSC's revenue recognition policy. 

Share
New Message
Please login to post a reply